Mosquito-borne disease

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Retrieved on: 
Tuesday, March 26, 2024
Notifiable disease, Saint-Herblain, Zika virus, JE, COVID-19, VLA2001, Ageing, Public, Chikungunya, Woman, Mosquito-borne disease, VLA, Safety, Euronext Paris, Access, CpG, Food, Vaccine

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

Key Points: 
  • Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
    the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
  • The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States.
  • Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety profile and immunogenicity in all tested doses and schedules2.
  • This preference stems from the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant.

Affordable stroke-risk screening could save the lives of many children in sub-Saharan Africa with sickle cell disease

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Brain, Sickle cell disease, Biomedical engineering, Risk, Patient, Stroke, Hospital, Mortality, Mosquito-borne disease, Malaria, Pain, Bangladesh Technical Education Board, Frequency, Medical imaging

As an assistant professor of biomedical engineering, I am working to reduce the likelihood that children born with sickle cell disease will die from stroke, one of the most common complications.

Key Points: 
  • As an assistant professor of biomedical engineering, I am working to reduce the likelihood that children born with sickle cell disease will die from stroke, one of the most common complications.
  • Sickle cell disease, whose name reflects the disease’s sickle or crescent moon shape of red blood cells, can affect any major organ, but my primary concern is its effect on the brain.
  • Without treatment, 11% of children with sickle cell disease will have a stroke before they turn 20 years old.
  • In fact, pain is the top reason that sickle cell patients go to the emergency room or hospital.

Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®

Retrieved on: 
Wednesday, November 22, 2023
Chikungunya, Vaccine, LTD, Research, Safety, Viral disease, Mosquito-borne disease, Sartorius, Temperature, FDA, Pharmaceutical industry

NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Key Points: 
  • Valneva's lyophilized chikungunya vaccine IXCHIQ® is the first in the world to be FDA approved against the viral disease, addressing an unmet medical need.
  • Recombumin®, a chemically defined, human and animal origin-free recombinant human albumin, is a critical enabler for the manufacture and formulation of Valneva's chikungunya vaccine.
  • NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus.
  • Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®

Retrieved on: 
Wednesday, November 22, 2023
Chikungunya, Vaccine, LTD, Research, Safety, Viral disease, Mosquito-borne disease, Sartorius, Temperature, FDA, Pharmaceutical industry

NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Key Points: 
  • Valneva's lyophilized chikungunya vaccine IXCHIQ® is the first in the world to be FDA approved against the viral disease, addressing an unmet medical need.
  • Recombumin®, a chemically defined, human and animal origin-free recombinant human albumin, is a critical enabler for the manufacture and formulation of Valneva's chikungunya vaccine.
  • NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus.
  • Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

SC Johnson Reaches Major Milestone with Breakthrough Mosquito Repellent Tool

Retrieved on: 
Wednesday, September 20, 2023
Science, Family medicine, SC, Public, Policy, Mosquito-borne disease, Season, Initiative, Jean Racine, School, S. C. Johnson & Son, Risk, WHO, World Health Organization, Malaria, Pharmaceutical industry, Typesetting, Guardian

New field testing shows SC Johnson spatial repellent could repel mosquitoes for multiple rainy seasons.

Key Points: 
  • Racine, Wisconsin--(Newsfile Corp. - September 20, 2023) - New field testing shows SC Johnson Guardian™, a spatial repellent made by SC Johnson, is demonstrating a game-changing efficacy of one year.
  • "Guardian's efficacy rate of one year is a game-changer because it covers multiple rainy seasons, when people are at higher risk for mosquito-borne disease," said SC Johnson Chairman and CEO, Fisk Johnson.
  • "We think we can make a big difference in eradicating malaria on this planet and we are making progress.
  • Frankly, SC Johnson's is the first tool I've seen in 36 years that has the promise of doing that."

The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial

Retrieved on: 
Thursday, August 3, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Vaccine, Human, Award, Fungus, National Institute of Allergy and Infectious Diseases, Fever, COVID-19, Mosquito-borne disease, Principal investigator, Cancer, NIH, Unitary state, Parasitism, Chikungunya, Multimedia, Temperature, Research, Infection, Cell, RNA, Doctor of Philosophy, Government, Bangladesh Technical Education Board, Rash, Science, Messenger, Infectious Disease Research Institute, Animal, Notifiable disease, Access, NLC, Immune system, Disease, Knowledge, Mortality, Geography, FDA, Headache, Virus

The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.

Key Points: 
  • The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.
  • AAHI’s approach to an RNA vaccine against chikungunya is distinctly different from the RNA vaccines which are currently approved by the FDA to prevent other diseases.
  • View the full release here: https://www.businesswire.com/news/home/20230803141024/en/
    AAHI RNA vaccine team evaluating preclinical data in the AAHI laboratory in Seattle, WA.
  • The goal of the award is to develop an effective chikungunya vaccine candidate that can reach endemic areas of the world.

Mosquito Joe® Shares Vital Tips to Safeguard Against Mosquitoes as Malaria Cases Resurface in U.S.

Retrieved on: 
Friday, June 30, 2023
Education, Chills, Breeding, Public, Fever, Mosquito-borne disease, IPM, Malaria, Associate, Fourth, CDC, DEET, EPA, Personal protective equipment, Korea Disease Control and Prevention Agency, Water, Anopheles, Nausea, Environment, News, Skin, Female, Disease, Tea, Heating, ventilation, and air conditioning

VIRGINIA BEACH, Va., June 30, 2023 /PRNewswire/ -- Mosquito Joe®, a Neighborly® company, is urging homeowners to take immediate action against mosquitoes following the public health alert issued by the Centers for Disease Control and Prevention (CDC) earlier this week, confirming the presence of malaria cases in Florida and Texas. These cases are the first instances of the mosquito-borne disease in the country since 2003. As nationwide concerns arise from this news, Mosquito Joe is committed to educating the public about the factors contributing to malaria transmission, its symptoms, and how to protect themselves ahead of the Fourth of July festivities.

Key Points: 
  • Malaria is a serious and potentially fatal disease that is transmitted through the bite of infected female Anopheles mosquitoes.
  • Though extremely rare in the U.S., there are more than 240 million cases of malaria diagnosed each year, according to the CDC.
  • At Mosquito Joe, we are committed to taking an active role in educating the public on effective mosquito prevention techniques to safeguard our communities from diseases like malaria."
  • Mosquito Joe is dedicated to helping homeowners protect themselves from the dangers of mosquitoes and the associated health risks.

Mosquito Joe® Sets the Stage for National Mosquito Control Awareness Week, Championing Global Health

Retrieved on: 
Tuesday, June 13, 2023
United Nations Foundation, Human, West Nile virus, Mosquito, Breeding, Public, Blood, Mosquito-borne disease, Yard, Malaria, Hematophagy, Zika virus, DEET, EPA, Risk, Personal protective equipment, Water, Dengue fever, Weather, Death, World Health Organization, Tea, Heating, ventilation, and air conditioning, Pharmaceutical industry, Zika fever

VIRGINIA BEACH, Va., June 13, 2023 /PRNewswire/ -- Mosquito Joe®, a Neighborly® company, is taking a proactive stance against mosquitoes as it kicks off National Mosquito Control Awareness Week, June 18-24. The leading pest control company aims to educate the public about protecting people and their homes from these blood-sucking pests while raising awareness about the diseases they potentially carry. The week also marks the launch of Mosquito Joe's Beat the Bloodsuckers campaign, a charitable initiative that aims to make a global impact by supporting those at the highest risk of mosquito-borne illnesses.

Key Points: 
  • VIRGINIA BEACH, Va., June 13, 2023 /PRNewswire/ -- Mosquito Joe® , a Neighborly® company, is taking a proactive stance against mosquitoes as it kicks off National Mosquito Control Awareness Week, June 18-24.
  • Mosquitoes are not just irritating pests disrupting outdoor summer activities; they pose a significant threat to public health as carriers of diseases.
  • Seek Professional Assistance: If you're dealing with a severe mosquito problem, consider hiring a professional pest control company like Mosquito Joe.
  • National Mosquito Control Awareness Week also marks the commencement of Mosquito Joe's 11th annual Beat the Bloodsuckers campaign, which aims to raise awareness about mosquito-borne illnesses and make a meaningful difference in communities worldwide.

SC Johnson Certifies 10,000 Rwandan Community Health Workers in the Fight Against Malaria

Retrieved on: 
Tuesday, April 25, 2023
Olive, Science, Family medicine, Poverty, HIV/AIDS, Partnership, University, Life, SC, Mosquito-borne disease, Society for Family Health Nigeria, Chantal, Woman, Community, EAC, Certification, UNITAID, Death, Molecular biology, Community health, S. C. Johnson & Son, Community health worker, Non-governmental organization, Nursing, MOU, Child, Reading, East African Community, Bill, Knowledge, Diagnosis, Growth, Notre Dame, Family, Caregiver, Female, Pharmaceutical industry, Vaccine, Society, Health, Malaria

RACINE, Wis., April 25, 2023 /PRNewswire/ -- Malaria is the seventh leading cause of death in Rwanda*, and an unexpected frontline of defense has emerged working to protect families and communities – it's tens of thousands of local community members, oftentimes the majority being women. The work these caregivers take on has a dramatic impact on their communities, but often at the expense of their own economic growth. As they spend days, weeks and months caring for their communities, it becomes nearly impossible to secure consistent work to support their families.

Key Points: 
  • Today, on World Malaria Day, SC Johnson, alongside Raid® and Society for Family Health Rwanda, celebrates the official certification of 10,000 Community Health Workers through Certified Care to help in the fight to eradicate malaria in Rwanda and provide them with official, paying positions.
  • Currently, Community Health Workers treat 55% of all malaria cases in Rwanda.
  • She has been a Community Health Worker for 15 years and believes Community Health Workers are the first line of defense against maternal and newborn deaths in Rwanda.
  • As she got older, she started noticing how important the Community Health Workers in her community were and became inspired by them.

Mosquito Joe® Urges Early Action for Mosquito Control and Prevention this Season

Retrieved on: 
Thursday, April 13, 2023
Neighborly, West Nile virus, Lyme disease, Education, Pest control, Mosquito-borne disease, Tick, IPM, Chikungunya, Zika virus, Snow, Associate, Centers for Disease Control and Prevention, DEET, EPA, Fever Dream, Risk, Personal protective equipment, Canine vector-borne disease, Water, Camping, Health, Environment, Disease, Malaria, Tea, Vaccine

VIRGINIA BEACH, Va., April 13, 2023 /PRNewswire/ -- Mosquito Joe®, a Neighborly® company, is taking the lead this season in early mosquito control and prevention, urging homeowners to take action against mosquitoes and ticks. With warmer winters in some regions across the country, peak mosquito season is fast approaching, and many areas will have a larger presence of bugs this year due to the accumulation of moisture and snow.

Key Points: 
  • VIRGINIA BEACH, Va., April 13, 2023 /PRNewswire/ -- Mosquito Joe ®, a Neighborly ® company, is taking the lead this season in early mosquito control and prevention, urging homeowners to take action against mosquitoes and ticks.
  • "With the recent moisture and snow accumulation, homeowners should take early action and protect themselves against the potential health risks posed by these pests."
  • Franchise locations across the US offer professional services that provide reliable and effective solutions for mosquito and tick control.
  • For more information about Mosquito Joe and how to take early action in pest control this year, visit MosquitoJoe.com.